Literature DB >> 21077527

Factors affecting maternal and perinatal outcomes in HELLP syndrome: evaluation of 126 cases.

M Erdemoğlu1, U Kuyumcuoğlu, A Kale, N Akdeniz.   

Abstract

OBJECTIVES: To ascertain the characteristics, clinical features, and maternal fetal outcome in HELLP (hemolysis elevated liver enzymes, low platelets) syndrome at a tertiary referral center.
MATERIAL AND METHODS: This was a cross-sectional study carried out at Dicle University between January 2004 and December 2008 in which the charts of 126 cases were retrieved retrospectively and data analyzed descriptively.
RESULTS: Of all deliveries 0.9% were complicated by HELLP syndrome. Of the cases with HELLP syndrome 79 (62.6%) had preeclampsia, 28 (22.2%) had eclampsia and 19 (15.2%) had a diagnosis of HELLP syndrome. The values of significant biochemical parameters (mean +/- SD) were documented as ALT (alanin aminotransferase) 224 +/- 42 IU/I and ALT1 (after birth) 140 +/- 22, AST 379 +/- 23 IU/l and AST1 215 +/- 51, LDH (lactate dehydrogenase) 1418 +/- 67 IU/l and LDH1 875 +/- 16, together with the hematological parameters as platelet count (86 +/- 12 K/Ul), urine protein (3 + in urine test stick) and albumin levels (2 + 0.9 g/dl). Eighty-six (68.25%) of the patients required albumin replacement. Thirty-one (24.6%) cases were nullipara and 95 (75.4%) multipara; of which 32 women (25.4%) were in Class I, and 94 (74.6 %) in Class II of complete HELLP syndrome. Regular antenatal examination was accomplished in a very small number of patients (12.25%). Fifty-eight (46.03%) patients required transfusions with blood or blood products and 12 (9.5%) underwent laparotomy due to major intraabdominal bleeding. Magnesium sulphate to prevent convulsions and corticosteroids (12 mg betametazone) to enhance fetal lung maturity were administered. Forty-four (34.9%) cases had vaginal delivery and 82 (65.1%) cesarean section; another 18 (14.2%) were with in utero stillbirth. Fifteen babies (11.9%) died, 26 (20.63%) developed placental abruption, 14 (11.11%) acute renal insufficiency, and 13 (10.31%) postoperative subcutaneous hematomas. Maternal mortality occurred in ten cases (7.93%).
CONCLUSION: HELLP syndrome is a pathology associated with a high incidence of maternal and perinatal complications. Laboratory parameters in cases with HELLP syndrome are not efficient in detecting perinatal results, but can be used as risk denominators in evaluating maternal complications. Therefore, for patients with HELLP syndrome, standard antenatal follow-up protocols should be applied in order to obtain early diagnosis and improve the speed of transfer to obstetric departments with expertise in this field.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21077527

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  4 in total

1.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

2.  Evaluation of Risk and Prognosis Factors of Acute Kidney Injury in Patients With HELLP Syndrome During Pregnancy.

Authors:  Lijuan Wang; Dongjie Tang; Haijun Zhao; Mingfeng Lian
Journal:  Front Physiol       Date:  2021-03-15       Impact factor: 4.566

Review 3.  Managing hepatic complications of pregnancy: practical strategies for clinicians.

Authors:  Maura Alice Morrison; Yooyun Chung; Michael A Heneghan
Journal:  BMJ Open Gastroenterol       Date:  2022-03

4.  Transfusion Related Acute Lung Injury after Cesarean Section in a Patient with HELLP Syndrome.

Authors:  Kyoung Min Moon; Min Soo Han; Ch'ang Bum Rim; So Ri Kim; Sang Ho Shin; Min Seok Kang; Jun Ho Lee; Jihye Kim; Sang Il Kim
Journal:  Korean J Fam Med       Date:  2016-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.